Search results for Iscalimab ELISA Kit
Iscalimab ELISA Kit, ProteoGenix, KPTX212
Description of Iscalimab ELISA Kit Introduction The Iscalimab ELISA Kit is a powerful tool for the detection and quantification of Iscalimab in various biological samples. Iscalimab, also known as CFZ533, is a fully human monoclonal antibody that targets the CD40-CD154 co-stimulatory pathway. This pathway plays a crucial role in the activation of T cells, making Iscalimab a promising therapeutic target for various autoimmune diseases and transplant rejection. In this article, we will discuss the structure, activity, and applications of the Iscalimab ELISA Kit in detail. Structure of Iscalimab Iscalimab is a 150 kDa glycosylated monoclonal antibody, composed of two heavy chains and two light chains. The heavy chains consist of a constant region and a variable region, while the light chains only have a variable region. The variable regions of both the heavy and light chains determine the specificity of Iscalimab for its target, CD40. The constant region of the heavy chains plays a role in the effector functions of Iscalimab, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Mechanism of Action Iscalimab works by binding to CD40 on the surface of T cells, blocking the interaction between CD40 and its ligand, CD154. This prevents the activation of T cells and subsequent production of inflammatory cytokines, such as interleukin-2 and interferon-gamma. Iscalimab also promotes the generation of regulatory T cells, which suppress immune responses and promote tolerance. These mechanisms make Iscalimab a potent immunosuppressant and a promising therapeutic option for autoimmune diseases and transplant rejection. Applications of Iscalimab ELISA Kit The Iscalimab ELISA Kit is a valuable tool for measuring the levels of Iscalimab in various biological samples, such as serum, plasma, and cell culture supernatants. This assay utilizes a sandwich enzyme-linked immunosorbent assay (ELISA) format, where a capture antibody specific for Iscalimab is coated onto a microplate. The Iscalimab present in the sample is then bound by the capture antibody, followed by the addition of a detection antibody specific for a different epitope on Iscalimab. The detection antibody is conjugated to an enzyme, which produces a colorimetric signal upon addition of a substrate. The intensity of this signal is directly proportional to the amount of Iscalimab present in the sample, allowing for accurate quantification. The Iscalimab ELISA Kit has several applications in research and clinical settings. In research, it can be used to monitor the pharmacokinetics of Iscalimab in preclinical and clinical studies. It can also be used to measure the levels of Iscalimab in patient samples to assess its efficacy as a therapeutic agent. In clinical settings, the Iscalimab ELISA Kit can be used to guide dosing and monitor treatment response in patients receiving Iscalimab therapy. Conclusion The Iscalimab ELISA Kit is a valuable tool for the detection and quantification of Iscalimab, a promising therapeutic antibody targeting the CD40-CD154 co-stimulatory pathway. Its accurate and sensitive measurement of Iscalimab levels in various biological samples makes it a valuable asset in research and clinical settings. With the increasing interest in Iscalimab as a therapeutic agent, the Iscalimab ELISA Kit is expected to play a crucial role in the development and monitoring of Iscalimab-based therapies for autoimmune diseases and transplant rejection. Keywords Antibody, therapeutic target, Iscalimab, CFZ533, CD40-CD154 co-stimulatory pathway, T cells, autoimmune diseases, transplant rejection, ELISA, pharmacokinetics, treatment response.
Host
Reactivity
Applications
Conjugation
Iscalimab ELISA Kit, Abbexa, abx395101
Iscalimab ELISA Kit is a quantitative ELISA kit for detection of Iscalimab.Iscalimab is a new, fully human, monoclonal antibody preventing cluster of differentiation 40 (CD40) pathway signaling and activation of CD40+ cell types. In a recent multicenter, randomized control trial (NCT02217410), with the primary endpoint of non-inferiority on the composite endpoint, iscalimab therapy showed non-inferiority on a composite clinical endpoint, improved renal function, reduced risk for new onset diabetes and similar safety compared with tacrolimus. The analysis presented at the ATC included patients from this study that underwent either routine biopsies or biopsies as part of a follow-up protocol. The data was reviewed and scored by a blinded pathologist using the established Banff criteria and CADI. A CADI of 1 or less was considered as 'normal renal histology'. The average CADI at final biopsy was 1.6 ±0.6 for iscalimab and 5.1 ±0.8 for tacrolimus.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.